Evidence map›Paper›PMID 40683772›Full record

Trial reportEBioMedicine2025

Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational study.

Milana Bergamino Sirvén, Elena López-Knowles, Xixuan Zhu, Holly Tovey, Lucy Kilburn, Chris Holcombe, Anthony Skene, John Robertson, Judith M Bliss, Anastasia Alataki and 4 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Milana Bergamino SirvénClinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK; Medical Oncology Department, Catalan Institute of Oncology-Badalona, Hospital Germans Trias I Pujol (HGTiP), 08916, Badalona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Elena López-KnowlesRalph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Xixuan ZhuClinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK.
Holly ToveyClinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK.
Lucy KilburnClinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK.
Chris HolcombeLiverpool University Hospitals Foundation Trust, Liverpool, UK.
Anthony SkeneRoyal Bournemouth and Christchurch and Christchurch NHS Foundation Trust, Bournemouth, UK.
John RobertsonFaculty of Medicine & Health Sciences, Queen's Medical Centre, Nottingham, UK.
Judith M BlissClinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK.
Anastasia AlatakiRalph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Ian SmithRoyal Marsden Hospital, London, UK.
Eugene F SchusterRalph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Mitch DowsettRalph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK.
Maggie Chon U CheangClinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK. Electronic address: Maggie.Cheang@icr.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbout 15-20% of breast cancers (BC) overexpress Human Epidermal Growth Factor Receptor 2 (HER2+), and 50% of them are also oestrogen receptor positive (ER+). Patients with ER+/HER2+ BC with a limited response to systemic therapies are at an increased risk of relapse, thus understanding the mechanisms of resistance is crucial. This study investigates the changes in gene signature expression (ΔGSE) within ER+/HER2+ tumours and their intrinsic subtype (IS) in response to peri-operative aromatase inhibitors (POAI).

methodsWe analysed paired pre-treatment (baseline) and on-treatment (2wk) samples from 313 ER+/HER2+ BC from the POETIC trial using the BC360™ codeset. Early biological response to aromatase inhibitors (AI) was assessed by immunohistochemical Ki67 levels. Association of ΔGSE with biological response was evaluated using T-test and time to recurrence (TTR) with multivariable Cox regression models adjusted for clinicopathological variables.

findingsThe immunity-related signatures were significantly upregulated, while proliferation, TP53 surrogate mutational status and ER-signalling were downregulated (FDR <0·05) among POAI tumours with low Ki67

interpretationAssessing on-treatment IS after POAI for ER+HER2+ BC can help to identify a group of low-risk patients with LumA

fundingCancer Research UK (CRUK/07/015).

Indexed as

Antineoplastic Agents, HormonalAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsNeoplasm Recurrence, LocalAgedAged, 80 and overDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMastectomyMiddle AgedNeoadjuvant TherapyAntineoplastic Agents, HormonalAromatase InhibitorsBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenAromatase inhibitorsBreast cancerHER2+Intrinsic subtypes

Identifiers

PMID40683772
PMCPMC12368290

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.